Search
Nitrous acid
go.drugbank.com/drugs/DB09112ApprovedInvestigationalIt is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. … There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections.
Categories: Compounds used in a research, industrial, or household settingOmidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigationalIn this group of patients, umbilical cord blood can be used as an alternative cell source since there is a lower risk of graft failure or graft-versus-host disease, even with low-grade HLA-matching. … [A258938,A258943,L46048] This type of cell therapy benefits patients that require stem cell transplantation as a treatment for blood cancers for whom a related or unrelated donor cannot be found due to
Synonyms: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)Trametinib
go.drugbank.com/drugs/DB08911ApprovedInvestigational[L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a … [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexAlirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/MLRopeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigationalhemorrhage and thromboembolic events, and a long-term propensity for myelofibrosis and leukemia. … [A242005] Ropeginterferon alfa-2b is a next-generation mono-pegylated type I interferon produced from proline-IFN-α-2b in _Escherichia coli_ that has high tolerability and a long half-life.
Products: BESREMi PenDobutamine
go.drugbank.com/drugs/DB00841ApprovedInvestigationalA beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.
Synonyms: 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamineMixtures: Dobutamine Hydrochloride in DextroseDeferiprone
go.drugbank.com/drugs/DB08826ApprovedInvestigationalDeferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. … Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired.
Categories: Compounds used in a research, industrial, or household settingProducts: GPO-L-One Tablet 500mgSimoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.
Products: Nuwiq 250IU Powder for Solution for Injection, Nuwiq 500IU Powder for Solution for InjectionZilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigational[L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.
Synonyms: -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-, N2-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA.Icosapent ethyl
go.drugbank.com/drugs/DB08887ApprovedInvestigationalNutraceuticalIcosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). … It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides.
Synonyms: E-EPA